- $21.43bn
- $21.97bn
- $2.07bn
- 93
- 11
- 99
- 76
Annual income statement for Insulet, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 904 | 1,099 | 1,305 | 1,697 | 2,072 |
| Cost of Revenue | |||||
| Gross Profit | 582 | 752 | 806 | 1,160 | 1,446 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 853 | 1,015 | 1,268 | 1,477 | 1,763 |
| Operating Profit | 51.5 | 83.6 | 37.6 | 220 | 309 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 9.7 | 20.5 | 9.8 | 215 | 300 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 6.8 | 16.8 | 4.6 | 206 | 418 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 6.8 | 16.8 | 4.6 | 206 | 418 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | 6.8 | 16.8 | 4.6 | 217 | 427 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.103 | 0.752 | 0.258 | 2.94 | 5.78 |